Intravenous Vitamin C Supplementation on the Quality of Sleep, Itching,Restlessleg Syndrome in Patients Undergoing Hemodialysis

Effect of Intravenous Vitamin C Supplementation on the Quality of Sleep, Itching,Restlessleg Syndrome in Patients Undergoing Hemodialysis In Tohid Hospital in Sanandaj at 2016

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20141208020249N4

Enrollment

Registered

2018-12-05

Start date

2015-04-02

Completion date

Unknown

Last updated

2019-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Chronic kidney disease. Condition 2: restless leg syndrome. Condition 3: Sleep Quality. Chronic kidney disease (CKD) Restless legs syndrome Insomnia, unspecified

Interventions

Intervention 1: Intervention group: People who need dialysis which referring to dialysis department of Sanandaj Tohid Medical CenterThe intervention group received a 5-cc (500 milligram) vial of vitam

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Patients with low sleep quality (score less than 5 based on global scores) Kidney failure, which has been dialyzed for at least 6 months signing Informed consent Kidney failure, which is dialyzed at least 3 times a week. Insomnia and or itching and or restless leg syndrome 18 to 70 years old

Exclusion criteria

Exclusion criteria: Dissatisfaction with the company in the study Failure to cooperate in completing the Petersburg quality of sleep questionnaire People who have recived vitamins C, E, or multi-vitamins containing vitamin C, E or fish oil during the two months before the study A history of mental illness, severe heart and respiratory disease, or a history of infectious disease three months before the study began. Taking immunosuppressive drugs in the last two months. Patients who have undergone kidney transplantation and returned to hemodialysis.

Design outcomes

Primary

Measure	Time frame
Itching. Timepoint: At the start of the study and after 8 weeks receiving the drug. Method of measurement: Level of itching according to VAS criteria.;Restless leg syndrome. Timepoint: At the start of the study and after 8 weeks receiving the drug. Method of measurement: history taking and Clinical Evaluation.;Sleep Quality. Timepoint: At the start of the study and after 8 weeks receiving the drug. Method of measurement: Pittsburgh Sleep Quality Standards Questionnaire (PSQI).	—

Measure

Time frame

Itching. Timepoint: At the start of the study and after 8 weeks receiving the drug. Method of measurement: Level of itching according to VAS criteria.;Restless leg syndrome. Timepoint: At the start of the study and after 8 weeks receiving the drug. Method of measurement: history taking and Clinical Evaluation.;Sleep Quality. Timepoint: At the start of the study and after 8 weeks receiving the drug. Method of measurement: Pittsburgh Sleep Quality Standards Questionnaire (PSQI).

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMinoo sadat Hajmiri

Sanandaj University of Medical Sciences

ehaj@yahoo.com008733664645

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026